Market ExpansionEyenovia's efforts to pursue an additional 200 active practices build on the current 230 offices for Mydcombi adoption, signaling potential expansion and increased market penetration.
Product DevelopmentEyenovia's streamlined second-generation Optejet device, intended for patient use, is part of development progression, opening future opportunities for adoption in myopia and collaborations for other eye conditions.
Regulatory ApprovalEyenovia retains two FDA approvals for its Optejet delivery system, enhancing its credibility and potential market presence.